心肾综合征 中国就医指南

Cardiorenal syndrome (CRS) is a pathophysiologic disorder in which acute or chronic dysfunction of the heart or kidneys induces acute or chronic dysfunction of the other organ. It is not a single disease but a spectrum of interrelated conditions classified into five subtypes (Type 1–5) based on the primary insult (cardiac vs. renal), temporal sequence (acute vs. chronic), and direction of organ crosstalk. Type 1 (acute CRS) involves abrupt worsening of cardiac function leading to acute kidney injury; Type 2 (chronic CRS) reflects chronic heart failure driving progressive chronic kidney disease; Type 3 (acute renocardiac syndrome) arises from acute kidney injury triggering acute cardiac events; Type 4 (chronic renocardiac syndrome) denotes chronic kidney disease contributing to decreased cardiac function and increased cardiovascular mortality; and Type 5 (secondary CRS) refers to systemic disorders (e.g., sepsis, diabetes, autoimmune vasculitis) causing simultaneous cardiac and renal dysfunction. Pathogenesis centers on neurohormonal activation (RAAS, SNS), inflammatory cytokine release, oxidative stress, endothelial dysfunction, hemodynamic imbalance (reduced renal perfusion, venous congestion), and maladaptive cardiorenal reflexes. Epidemiologically, CRS affects an estimated 25–40% of hospitalized heart failure patients and up to 60% of those with advanced chronic kidney disease; prevalence rises sharply with age, comorbid diabetes, hypertension, and prior cardiovascular events. Risk factors include advanced age (>65 years), diabetes mellitus, arterial hypertension, coronary artery disease, atrial fibrillation, obesity, chronic kidney disease (eGFR <60 mL/min/1.73m²), proteinuria, and recurrent hospitalizations for decompensated heart failure. CRS profoundly impairs quality of life: patients experience debilitating fatigue, dyspnea, orthopnea, peripheral edema, reduced exercise tolerance, sleep disturbances, anxiety, depression, and social isolation. Frequent hospital readmissions, polypharmacy burden, dietary restrictions (low-sodium, low-potassium, fluid-limited regimens), and progressive functional decline severely limit independence and daily activities. Early diagnosis remains challenging due to overlapping symptoms (e.g., weight gain, oliguria, elevated BNP, rising creatinine) and lack of standardized biomarkers beyond serum creatinine, cystatin C, NT-proBNP, and novel markers like NGAL or TIMP-2•IGFBP7 under investigation. Multidisciplinary management—integrating nephrology, cardiology, and palliative care—is essential to mitigate progression, optimize volume status, preserve residual renal function, and improve survival.

# 心肾综合征治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：1型（急性心衰诱发急性肾损伤）、2型（慢性心衰合并CKD 3–4期）患者，eGFR ≥15 mL/min/1.73m²，无严重血流动力学障碍。

• •基础药物治疗（含利尿、RAASi、β受体阻滞剂、SGLT2i）：月均药费 800–3,200元（国产仿制药 vs 原研药）
• •血液净化支持（CRRT或间歇HD）：单次费用 2,800–6,500元（含管路、置换液、抗凝监测）；周均2–3次，月均 25,000–58,000元
• •检验检查费（BNP、NT-proBNP、肌钙蛋白、胱抑素C、尿NGAL、心脏超声、肾脏超声）：首诊 1,200–2,600元，随访月均 600–1,500元

二、介入/核心治疗方案

适用人群：合并严重冠脉病变（SYNTAX≥22）、难治性心衰伴左室射血分数＜35%者，需多学科评估后决策。

• •冠状动脉介入（PCI）+优化心肾管理：术前检查（冠脉CTA+心肾功能评估） 3,500–5,200元；PCI总费用（含支架） 48,000–126,000元（金属支架 vs 药物涂层支架）
• •心脏再同步化治疗（CRT）联合肾功能保护：术前评估 4,800–7,000元；CRT植入术 186,000–298,000元（含起搏器及术后3个月肾功能动态监测）

三、特殊复杂/晚期方案

适用人群：终末期心肾双衰（NYHA IV级+CKD 5期透析依赖）、多器官功能障碍、耐药性水肿。

• •联合脏器支持（IABP+CRRT+正性肌力药泵入）：日均费用 12,000–22,000元，7日疗程约 84,000–154,000元
• •心脏移植评估+长期透析过渡：评估费 28,000–45,000元；维持透析年均 120,000–180,000元

四、方案快速选择指南

• •预算≤5万元/年：优选药物+CRRT保守治疗（eGFR＞30者）
• •预算15–50万元/年+中重度冠脉病变：PCI联合肾保护方案
• •晚期双器官衰竭+家庭支持强：启动移植评估+联合支持治疗